ArticleBMC gastroenterology2016
Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats.
Article in BMC gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Gut microbiota and ALS: cause, consequence or correlation? - a systematic review.Frontiers in neuroscience · 2026Pooled it
- Dietary inflammatory index and the risk of colorectal adenomas and cancer: a systematic review and dose-response meta-analysis.Nutrition journal · 2025Pooled it
- Protective effect of the "food-microorganism-SCFAs" axis on colorectal cancer: from basic research to practical application.Journal of cancer research and clinical oncology · 2019Pooled it
- Lactobacillus plantarum CCFM639 Alleviates Hypertension by Reshaping Gut Microbiota and Regulating Key Metabolites.Probiotics and antimicrobial proteins · 2026Trial
- The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future.Gut microbes · 2026Review
- Gut microbial signatures in poultry under low-protein diets and lysine restriction: implications for precision nutrition.Veterinary and animal science · 2026Review
- Faecalibacterium prausnitzii: Mechanistic Insights and Therapeutic Potential in Host-Microbe Crosstalk.Probiotics and antimicrobial proteins · 2026Review
- Oral Nanomicelle-Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Phytochemicals remodel antitumor immunity via the "microbiota-metabolite-receptor" axis: focus on colorectal cancer and immunotherapy.Medical oncology (Northwood, London, England) · 2026Review
- Oral-Gut Microbiome Axis in Crohn's Disease: A Potential Role of Ectopic Colonization.Microorganisms · 2026Review
- Microbiota-Driven Strategies for Managing IBD-Associated Risks: From Infections to Mental Health.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies.Clinical and molecular hepatology · 2026Review
- Article
- The intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance ofGut microbes · 2025Article
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- Butyrate, IL-4, and EP4 Receptors: A Triad of Colorectal Homeostasis, Protecting Against Onset of Cancer and IBD?BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- B12 promotes gut dysbiosis and an inflammatory microenvironment that potentiatesbioRxiv : the preprint server for biology · 2025Article
- Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.Pathogens (Basel, Switzerland) · 2025Review
- [Research progress in gut microbiota and metabolism in the pathogenesis of chronic urticaria].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy.Immunotherapy · 2025Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundButyrate is an energy source for colonocytes that is formed by bacterial fermentation of dietary fiber in the colon and that exerts broad anti-inflammatory activities. Although the administration of butyrate improves homeostasis in patients and ameliorates IBD (Inflammatory Bowel Disease)-related lesions and symptoms, the anti-inflammatory mechanisms of butyrate still remain unclear. To explore the impact of butyrate on Treg (Regulatory T cell)/Th17 (T helper 17 cell) differentiation and colitis in rats.
methodsThe effect of butyrate on the expression of markers related to both Tregs and Th17 cells were determined in human monocytes as well as a rat model of colitis induced by 2,4,6-trinitrobenzene sulfonic acid. Rats were treated with butyrate in vivo, whereas the rat splenocytes and human monocytes were treated in vitro.
resultsWe found that butyrate administration increased peripheral blood Treg cell levels as well as plasma levels of anti-Th17 cytokines (IL-10 and IL-12). Butyrate administration further suppressed IL-17 levels in both plasma and colonic mucosa, and ameliorated colonic colitis lesions in rats. This promotion of Treg activity and inhibition of IL-17 release was also observed in human venous monocytes and rat splenocytes in vitro.
conclusionsOur results suggest that butyrate plays a key role in regulating the Treg/Th17 balance and ultimately protects the colon mucosa against the development of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.